- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01884701
Accessing Peripheral Occluded LesiOns II (APOLO-II) (APOLO-II)
13. oktober 2016 opdateret af: EndoCross Ltd.
The current study is a prospective, single-arm, non-randomized, multi-center study to evaluate the outcome of the ENABLER-P Catheter System for crossing chronic total occlusions during endovascular intervention for femoral-popliteal occlusive disease.
Studieoversigt
Status
Trukket tilbage
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Fase
- Fase 3
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Documentation from a previous attempt OR a concurrent reasonable attempt (at least 5 minutes) during this procedure, demonstrating resistance to conventional guidewire crossing;
- Patient must have objective evidence of lower extremity ischemia;
- Totally occlusive lesion in a native femoropopliteal artery classified angiographically as absolute (100% occlusion with no flow), where no antegrade filling beyond the occlusion is visible;
- Target occlusion length is >1cm and ≤ 30 cm;
- Patient's reference vessel diameter is ≥ 4.0 mm and ≤6.0 mm (by visual angiographic estimation)
- Patient must be an acceptable candidate for PTA, peripheral artery bypass surgery or peripheral artery stent implantation;
- Female patients of child bearing potential must have a negative pregnancy test within 48 hours prior to the study procedure;
- Patient must have been informed of the nature of the study, agree to its provisions, and provide written informed consent;
- Patient is ≥ 21 years of age.
Exclusion Criteria:
- Patient has hypersensitivity or contraindication to aspirin, heparin, Plavix or radiographic contrast agents which cannot be adequately pre-medicated;
- The patient requires immediate treatment in more than one occluded vessel, in any combination of grafts or native vessels;
- Patient has planned femoropopliteal intervention scheduled within 30 days after index procedure;
- The patient is currently participating in another investigational drug or device trial that may conflict with study data collection and has not completed the entire follow-up period;
- Patient has no collateral flow distal to the occlusion;
- Patient's target occlusion has a dissection that occurred within the past 30 days caused by a guidewire attempt;
- Patient has a history of bleeding diatheses, coagulopathy or will refuse blood transfusion in cases of emergency;
- Patient suffered recent (within the past 6 months) significant gastrointestinal (GI) bleeding;
- Patient's target lesion or the vessel proximal to the target lesion reveals significant ectasia, dissection, aneurysm or thrombus;
- Patient has other medical illnesses (i.e., cancer or congestive heart failure) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with life-expectancy less than 1 year.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The primary safety endpoint of this study is to evaluate in hospital and 30 day major adverse events ("MAEs"), clinically significant perforations, clinically significant embolization and/or Grade C or greater dissections.
Tidsramme: 30 days (+/-7 days)
|
30 days (+/-7 days)
|
|
Advancement of the ENABLER-P supported guidewire into or through the CTO in native femoropopliteal artery and subsequent achievement of distal vessel guidewire position with any conventional guidewire.
Tidsramme: 30 days (+/-7 days)
|
30 days (+/-7 days)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2013
Primær færdiggørelse (Forventet)
1. oktober 2016
Datoer for studieregistrering
Først indsendt
19. juni 2013
Først indsendt, der opfyldte QC-kriterier
21. juni 2013
Først opslået (Skøn)
24. juni 2013
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
17. oktober 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
13. oktober 2016
Sidst verificeret
1. marts 2015
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- IVO-031
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Femoropoliteal okklusiv sygdom
-
BrosMed Medical Co., LtdIkke rekrutterer endnuFemoropopliteal arteriestenoser eller okklusiv læsionerKina
-
Assistance Publique - Hôpitaux de ParisIkke rekrutterer endnuFemoropopliteal læsionFrankrig
-
Midwest Cardiovascular Research FoundationAfsluttetFemoropopliteal In-stent RestenoseForenede Stater
-
Spectranetics CorporationYale UniversityTrukket tilbage
-
Cliniques universitaires Saint-Luc- Université...UkendtFemoropopliteal arteriel stenoseBelgien
-
Chunshui HeDepartment of Vascular Surgery, The First Affiliated Hospital of Medicine... og andre samarbejdspartnereIkke rekrutterer endnuFemoropopliteal In-Stent Restenose (ISR)
-
Genoss Co., Ltd.Ikke rekrutterer endnuFemoropoliteal arteriesygdom | PTA (perkutan transluminal angioplasti) | Lang Femoropopliteal ArteriesygdomSydkorea
Kliniske forsøg med ENABLER-P Catheter System
-
Oregon Research InstituteNational Institute on Drug Abuse (NIDA)AfsluttetAttention Deficit Hyperactivity Disorder | Adfærdsforstyrrelse | Oppositionel Defiant Disorder | Børns forstyrrende adfærdsforstyrrelserForenede Stater
-
LVD Biotech S.LAktiv, ikke rekrutterendeBlødning | Åreknuder | Aneurisme | Vaskulære anomalier | Pseudoaneurisme | Portal veneembolisering | Hypervaskulær tumor | Type II endolækage | Patologisk organSpanien
-
Medical University of South CarolinaAfsluttet
-
Benha UniversityAfsluttetKomplikationer ved kejsersnit | Unormal livmoderblødning | Uterin arEgypten
-
Privo TechnologiesNational Cancer Institute (NCI)RekrutteringOralt planocellulært karcinomForenede Stater
-
Medtronic Spinal and BiologicsAfsluttetDegenerativ diskussygdom
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID) og andre samarbejdspartnereAfsluttet
-
Zealand University HospitalHvidovre University HospitalAktiv, ikke rekrutterendeSkuldersmerter | Skulder slidgigt | SkuldergigtDanmark
-
University of AarhusRegionshospitalet Hammel Neurocenter; Finnish Institute of Occupational... og andre samarbejdspartnereAfsluttet
-
Marmara UniversityUkendt